Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks

Abstract

Introduction

In a 52-week, phase 3 clinical trial (LIBERTY AD CHRONOS) in adult patients with moderate-to-severe atopic dermatitis (AD), dupilumab in combination with topical corticosteroids (TCS) resulted in a significant improvement in overall Eczema Area and Severity Index (EASI) compared with placebo plus TCS. In a post hoc analysis, dupilumab significantly improved the overall extent and severity of AD across four anatomic regions (head and neck, trunk, upper extremities, lower extremities) over 16 weeks. However, as AD severity and presentation may vary by body region, this analysis sought to determine whether there are regional variations in dupilumab efficacy.

Methods

Using data from the LIBERTY AD CHRONOS study, we performed a post hoc analysis of the mean percentage change in individual EASI signs (erythema, infiltration/papulation, excoriation, lichenification) from baseline through week 52 across four anatomic regions (head and neck, trunk, upper extremities, lower extremities).

Results

Dupilumab plus TCS, compared with placebo plus TCS, significantly improved the severity of all individual AD signs to a similar extent across the four anatomic regions. Significant improvements in each sign were seen early, within the first 2–4 weeks of treatment, and were sustained through week 52 across all regions.

Conclusions

In adult patients with moderate-to-severe AD, treatment with dupilumab resulted in rapid and sustained improvement in the signs of AD across all anatomic regions.

Trial registration

LIBERTY AD CHRONOS (NCT02260986).

Key Summary Points

Why carry out this study?

In phase 3 trials in adults with moderate-to-severe atopic dermatitis (AD), treatment with dupilumab resulted in a substantial reduction in overall disease severity.

Dupilumab was equally efficacious in reducing AD severity in four anatomic regions measured by Eczema Area and Severity Index (EASI) over 16 weeks.

As AD severity and presentation may vary by body region, the objective of this analysis was to characterize the efficacy of dupilumab with respect to individual AD signs across four anatomic regions as assessed by EASI over 52 weeks in adults with moderate-to-severe AD.

What was learned from the study?

Dupilumab demonstrated rapid and sustained improvement, maintained through 52 weeks, in the individual signs of AD across all anatomic regions in adults with moderate-to-severe AD.

Introduction

The presentation of atopic dermatitis (AD) can differ by anatomic region, with morphologic variants showing predispositions for certain body areas [1]. Facial regions and areas with skin flexures may show a range of AD signs [1]. Sensitive areas with thinner skin, such as the head and neck, may be more susceptible to irritants and allergens, and vulnerable to skin-thinning effects of topical corticosteroids (TCS) [2].

Dupilumab, a monoclonal antibody that blocks the shared receptor component for interleukin (IL)-4 and IL-13 [3–6], has demonstrated significant efficacy and an acceptable safety profile in patients with moderate-to-severe AD and other type 2 inflammatory diseases [7–16].

In the 52-week LIBERTY AD CHRONOS study, dupilumab plus TCS, compared with placebo plus TCS, resulted in a significant improvement in overall Eczema Area and Severity Index (EASI) [10]. In a 16-week analysis of four clinical trials in adults with moderate-to-severe AD, including LIBERTY AD CHRONOS, dupilumab plus TCS compared with placebo plus TCS significantly improved the extent and severity of AD across four anatomic regions (head and neck, trunk, upper extremities, lower extremities) as assessed by EASI [17].

Although no safety signal was detected during randomized clinical trials of dupilumab in AD, a number of individual case reports and limited case series describe a new-onset or acute worsening of facial rash associated with dupilumab treatment [18–28]. Reported clinical signs and symptoms include erythema, edema, flushing, papulopustules, pruritus, scaling, and a burning sensation in the centrofacial area [26, 28]. Various possible etiologies have been suggested, including corticosteroid withdrawal, rosacea, contact dermatitis, Malassezia colonization involving the face and neck, seborrheic dermatitis, photosensitivity, and alcohol-induced facial flushing [19, 20, 22–25, 28, 29].

EASI is a composite score encompassing severity of AD signs and extent of disease over four anatomic regions: head/neck, upper extremities, trunk, and lower extremities. To further evaluate whether certain anatomic areas may respond in a differential manner to dupilumab therapy, we analyzed the change, over 52 weeks, in individual EASI signs (erythema, infiltration/papulation, excoriation, lichenification) across the four anatomic regions in patients included in the LIBERTY AD CHRONOS study.

Methods

We performed a post hoc analysis of data from the randomized, double-blinded, placebo-controlled, multicenter, parallel group, phase 3 LIBERTY AD CHRONOS trial (NCT02260986) of dupilumab [10]. The full study design and patient population of LIBERTY AD CHRONOS have been previously reported [10]. Briefly, LIBERTY AD CHRONOS enrolled adult patients (at least 18 years of age) with moderate-to-severe AD inadequately controlled with TCS. Patients were randomized 3:1:3 to receive dupilumab 300 mg subcutaneously (SC) once weekly (qw; with a loading dose of 600 mg), dupilumab 300 mg SC every 2 weeks (q2w; with a loading dose of 600 mg), or placebo qw, respectively, for a period of 52 weeks. All patients received a concomitant standardized regimen of medium-potency TCS, which could be tapered, stopped, or restarted on the basis of disease activity.

LIBERTY AD CHRONOS was conducted in accordance with the provisions of the Declaration of Helsinki, the International Conference on Harmonisation Good Clinical Practice guideline (version R1), and applicable regulatory requirements. All patients provided signed written informed consent. The protocol and all relevant study forms were approved by all relevant institutional review boards and an independent ethics committee.

Endpoints

EASI is a validated measure to assess the severity and extent of AD [30]. The score is a composite of the investigator’s assessment of the severity of four individual signs (erythema, infiltration/papulation, excoriation, and lichenification) rated on a scale of 0 (absent) through 3 (severe), and the extent of AD involvement assessed as a percentage of body surface area in each of four anatomic regions (head and neck, trunk, upper extremities, lower extremities) converted to a score of 0 to 6 as follows: 0 (0%), 1 (1–9%), 2 (10–29%), 3 (30–49%), 4 (50–69%), 5 (70–89%), or 6 (90–100%).

For each region, the severity of the four signs is summated (0–12) and then multiplied by the extent of involvement (0–6). Least squares (LS) mean percentage change in EASI from baseline through week 52 for each of the four AD signs was evaluated in four anatomic regions.

Analysis

Only data for patients who received the approved dupilumab dose regimen of 300 mg q2w plus TCS, or placebo plus TCS in the study, were included in this post hoc analysis.

Endpoints were analyzed using an analysis of covariance model with baseline measurement as covariate and the treatment, randomization strata (baseline disease severity [Investigator’s Global Assessment (IGA) = 3 vs IGA = 4]), and geographical region as fixed factors.

Values after rescue medication use were set to missing. For LS mean percentage change in EASI signs, missing values were imputed using the last observation carried forward method. p < 0.05 (two-sided tests) was regarded as significant. Since this analysis was post hoc, and not adjusted for multiplicity, the p values provided in the manuscript are nominal. Statistical Analysis Software, version 9.4 (SAS Institute, Inc; Cary, NC, USA) was used for all analyses.

Results

In the LIBERTY AD CHRONOS study, 740 patients were enrolled (319 dupilumab 300 mg qw plus TCS, 106 dupilumab 300 mg q2w plus TCS, and 315 placebo plus TCS) [10]. In the present analysis, 421 patients were included: 106 patients who received the approved adult dose regimen of dupilumab 300 mg q2w plus TCS (median age 40.5 years; 58% male) and the 315 patients who received placebo plus TCS (median age 34.0 years; 61% male) [10]. Baseline demographics and clinical characteristics of all patients included in LIBERTY AD CHRONOS (including overall EASI values) have been previously reported and were similar between the dupilumab plus TCS and placebo plus TCS groups [10].

At baseline, EASI for individual signs across anatomic regions was similar between the dupilumab 300 mg q2w plus TCS and placebo plus TCS groups (Fig. 1). Dupilumab 300 mg q2w plus TCS significantly improved each individual EASI sign in all four anatomic regions, including lichenification, the AD sign most resistant to treatment (Fig. 1) [31]. Significant improvements were seen in most cases as early as week 2, and in all cases as early as week 4, with further improvements through week 16, which were maintained through week 52.

Fig. 1.

LS mean percentage change in EASI for erythema, infiltration/papulation, excoriation, and lichenification from baseline to week 52 by visit in four anatomic regions. *p < 0.05 vs placebo; **p ≤ 0.01 vs placebo; ***p ≤ 0.001 vs placebo. BL baseline, EASI Eczema and Severity Index, LS least squares, q2w every 2 weeks, SD standard deviation

With respect to erythema, significant improvements with dupilumab plus TCS were seen in the head/neck, trunk, and lower extremities as early as week 2 and in the upper extremities by week 4. At week 52, placebo-corrected improvements in erythema were similar in all regions, ranging from − 30.0 in the head and neck region to − 34.8 in the lower extremity region, although the LS mean percentage change from baseline in the dupilumab plus TCS treatment group in the head and neck region (− 65.1%) was slightly lower than the improvement observed in other regions, which ranged from − 70.5% to − 75.7%. A similar pattern was also observed for the signs of infiltration/papulation and excoriation in the head and neck region vis-a-vis the other three regions (i.e., numerically lower placebo-corrected differences and lower absolute mean change from baseline). A body map illustrating LS mean percentage change in EASI at week 52 for each sign in each anatomic region is displayed in Fig. 2.

Fig. 2.

Body map^a showing LS mean percentage change in EASI for erythema, infiltration/papulation, excoriation, lichenification at baseline and at week 52 in four anatomic regions. ^aFor graphical purposes, figures have been constructed to represent the right side of the body being treated with placebo and the left side being treated with dupilumab. In patients receiving dupilumab, similar responses were achieved on both sides of the body. EASI Eczema Area and Severity Index, LS least squares

Discussion

Dupilumab plus TCS significantly improved the severity of individual AD signs across four anatomic regions as assessed by EASI in the randomized, placebo-controlled phase 3 LIBERTY AD CHRONOS trial in adults with moderate-to-severe AD.

The results, which show comparable improvements across anatomic regions, confirm and extend the short-term results seen in adults with moderate-to-severe AD who received dupilumab with or without TCS [17]. Improvements in all regions and signs were seen early, after the first or second dupilumab dose, and were maintained through week 52. Dupilumab was generally well tolerated with an acceptable safety profile in the LIBERTY AD CHRONOS study [10].

Facial AD lesions may have a higher impact on a patient’s quality of life than AD lesions in other anatomic regions [32], as it is a highly visible and an aesthetically important site. Recent studies have described new-onset or acute worsening of facial rash and posited various etiologies—many of which are presumably unrelated to dupilumab treatment—including rosacea, allergic contact dermatitis, Malassezia colonization involving the face and neck, photosensitivity, and steroid withdrawal [18–28]. The face is a common site for exacerbation by irritants and/or allergic contact dermatitis [33]. For most patients with AD and allergic contact dermatitis, identification and avoidance of the contact allergen is the only definitive management approach [34]. Additionally, steroid withdrawal can trigger rebound erythema in the head and neck region while fluorinated TCS can trigger rosacea or periorificial facial dermatitis [35–38]. In this analysis, improvement in erythema score for the head and neck region was comparable to, albeit slightly lower than, that seen in other regions, suggesting that instances of facial rash associated with dupilumab treatment reported in the literature are unlikely to represent AD lesions recalcitrant to dupilumab treatment and arise independently of the IL-4/IL-13 pathway. This observation may also suggest that the head and neck region is a more difficult area to treat.

A limitation is the inability to further subdivide EASI assessment parameters within each anatomic region. For example, AD signs in the head and neck region cannot specifically discern changes in signs in the facial region, nor can evaluation of signs in the upper extremities specifically assess changes in the hands.

Conclusions

In LIBERTY AD CHRONOS, a randomized, double-blinded, placebo-controlled phase 3 trial in adults with moderate-to-severe AD, treatment with dupilumab resulted in comparable improvements in AD signs (erythema, infiltration/papulation, excoriation, and lichenification) across four anatomic regions (head and neck, trunk, upper extremities, lower extremities). Improvements in all signs in each anatomic region were seen early, after the first or second dupilumab dose, and were sustained through week 52. Dupilumab was generally well tolerated with an acceptable safety profile.